Estatísticas Básicas
| LEI | 5299003EUHV3CD08L949 |
| CIK | 882361 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Aptose Biosciences Inc.
SEC Filings (Chronological Order)
Esta página fornece uma lista completa e cronológica de Arquivamentos da SEC, excluindo os arquivamentos de propriedade que fornecemos em outro lugar.
| May 29, 2026 |
EXHIBIT 99.1 Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical SAN DIEGO and TORONTO, May 29, 2026 (GLOBE NEWSWIRE) - Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF) announced today that closing of the previously announced arrangement (the “Arrangement”) with Hanmi Pharmaceutical Co. Ltd. (“Hanmi”) a |
|
| May 29, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2026 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 13, 2026 |
Aptose Reports First Quarter 2026 Results EXHIBIT 99.1 Aptose Reports First Quarter 2026 Results SAN DIEGO and TORONTO, May 13, 2026 (GLOBE NEWSWIRE) - Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced financial result |
|
| May 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2026 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q on UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 1-32001 APTOSE BIOSCIENCES |
|
| April 30, 2026 |
EXHIBIT 99.1 Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical SAN DIEGO and TORONTO, April 30, 2026 (GLOBE NEWSWIRE) - Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF) announced today that closing of the previously announced arrangement (the “Arrangement”) with Hanmi Pharmaceutical Co. Ltd. (“Hanmi”) |
|
| April 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2026 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| April 1, 2026 |
SC 13E3/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13E-3 RULE 13E-3 TRANSACTION STATEMENT UNDER SECTION 13(e) OF THE SECURITIES ACT OF 1934 (Amendment No. 4) APTOSE BIOSCIENCES INC. (Name of the Issuer) Aptose Biosciences Inc. Hanmi Science Co. Ltd. Hanmi Pharmaceutical Co. Ltd. HS North America Ltd. (Names of Persons Filing Statement) Common Shares, no par |
|
| March 31, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2026 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| March 31, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-32001 Aptose Bioscien |
|
| March 31, 2026 |
EXHIBIT 99.1 Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and Corporate Highlights Shareholders approve acquisition of Aptose by Hanmi Pharmaceutical in “Go Private” transaction TUS+VEN+AZA triplet frontline therapy continues to demonstrate favorable safety and high rates of eff |
|
| March 31, 2026 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of the Registrant Name State/Jurisdiction of Incorporation Aptose Biosciences U.S. Inc. Delaware NuChem Pharmaceuticals Inc. Ontario, Canada |
|
| March 31, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2026 APTOSE BIOSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| March 23, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2026 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| March 23, 2026 |
EXHIBIT 99.1 Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement Shareholders are Recommended to Vote “FOR” the Aptose Biosciences Proposed Plan of Arrangement with Hanmi Pharmaceutical Shareholders are Reminded of Voting Deadline for Upcoming Special Meeting SAN DIEGO and TORONTO, March 23, 2026 (GLOBE NEWSWIRE) - Aptose Biosciences Inc. (“Aptose” or the “Compa |
|
| March 23, 2026 |
AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT EX-10.1 Exhibit 10.1 AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT This Amendment to the Second Amended and Restated Executive Employment Agreement (“Amendment”) is made and entered into as of this 12th, day of March, 2026 (the “Effective Date”) by and between Aptose Biosciences Inc. (the “Corporation”) and Dr. William G. Rice (“Executive”). As used in this Amendment, “Party” means either the Corpor |
|
| March 23, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2026 APTOSE BIOSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| March 23, 2026 |
RW Aptose Biosciences Inc. 66 Wellington Street West, Suite 5300 TD Bank Tower, Box 48 Toronto, Ontario M5K 1E6 Canada March 23, 2026 VIA EDGAR Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Aptose Biosciences Inc. Withdrawal of Registration Statement on Form S-1 File No. 333-284927 Ladies and Gentlemen: Pursuant to Rule 477 of the |
|
| March 19, 2026 |
EXHIBIT 99.1 Leading Independent Proxy Advisory Firm ISS Recommends Aptose Biosciences Shareholders Vote “FOR” Proposed Plan of Arrangement with Hanmi Pharmaceutical SAN DIEGO and TORONTO, March 19, 2026 (GLOBE NEWSWIRE) - Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF) today announced that Institutional Shareholder Services (“ISS”), a leading independent proxy advisory |
|
| March 19, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2026 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| February 24, 2026 |
EX-99.1 Exhibit 99.1 Not For Immediate Release – Strictly Confidential – For Review Aptose Biosciences Announces Amendment to Arrangement Agreement and Details of Postponed Special Meeting of Shareholders Aptose Biosciences and Hanmi Pharmaceutical to Further Extend Loan Agreement to Continue Development of Tuspetinib in Frontline Triplet Therapy for AML SAN DIEGO and TORONTO, February 23, 2026 — |
|
| February 24, 2026 |
DEFM14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| February 24, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2026 APTOSE BIOSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 24, 2026 |
EX-10.1 Exhibit 10.1 Execution Version SECOND AMENDED AND RESTATED 2025 FACILITY AGREEMENT between Hanmi Pharmaceutical Co., Ltd., as Lender and Aptose Biosciences Inc., as Borrower and Aptose Biosciences U.S. Inc. and NuChem Pharmaceuticals Inc., each as a Guarantor This second amended and restated 2025 facility agreement is dated February 23, 2026. PARTIES Hanmi Pharmaceutical Co., Ltd. incorpor |
|
| February 24, 2026 |
EX-2.1 Exhibit 2.1 Execution Version APTOSE BIOSCIENCES INC. and HS NORTH AMERICA LTD. and HANMI PHARMACEUTICAL CO. LTD. AMENDED AND RESTATED ARRANGEMENT AGREEMENT FEBRUARY 23, 2026 B-1 TABLE OF CONTENTS ARTICLE 1 INTERPRETATION 1 Section 1.1 Defined Terms. 1 Section 1.2 Certain Rules of Interpretation. 20 ARTICLE 2 THE ARRANGEMENT 21 Section 2.1 Arrangement. 21 Section 2.2 Interim Order. 21 Secti |
|
| February 24, 2026 |
SC 13E3/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13E-3 RULE 13E-3 TRANSACTION STATEMENT UNDER SECTION 13(e) OF THE SECURITIES ACT OF 1934 (Amendment No. 3) APTOSE BIOSCIENCES INC. (Name of the Issuer) Aptose Biosciences Inc. Hanmi Science Co. Ltd. Hanmi Pharmaceutical Co. Ltd. HS North America Ltd. (Names of Persons Filing Statement) Common Shares, no par |
|
| February 17, 2026 |
PRER14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| February 17, 2026 |
SC 13E3/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13E-3 RULE 13E-3 TRANSACTION STATEMENT UNDER SECTION 13(e) OF THE SECURITIES ACT OF 1934 (Amendment No. 2) APTOSE BIOSCIENCES INC. (Name of the Issuer) Aptose Biosciences Inc. Hanmi Science Co. Ltd. Hanmi Pharmaceutical Co. Ltd. HS North America Ltd. (Names of Persons Filing Statement) Common Shares, no par |
|
| February 9, 2026 |
PRER14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| February 9, 2026 |
SECOND AMENDED AND RESTATED INVESTOR’S RIGHTS AGREEMENT EX-99.(d)(iii) Exhibit (d)(iii) SECOND AMENDED AND RESTATED INVESTOR’S RIGHTS AGREEMENT This SECOND AMENDED AND RESTATED INVESTOR’S RIGHTS AGREEMENT (this “Agreement”), is made as of March 18, 2025, by and between Aptose Biosciences Inc., a Canadian corporation (the “Company”), and Hanmi Pharmaceutical Co., Ltd., a corporation incorporated under the laws of the Republic of Korea (the “Investor”). |
|
| February 9, 2026 |
SC 13E3/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13E-3 RULE 13E-3 TRANSACTION STATEMENT UNDER SECTION 13(e) OF THE SECURITIES ACT OF 1934 (Amendment No. 1) APTOSE BIOSCIENCES INC. (Name of the Issuer) Aptose Biosciences Inc. Hanmi Science Co. Ltd. Hanmi Pharmaceutical Co. Ltd. HS North America Ltd. (Names of Persons Filing Statement) Common Shares, no par |
|
| January 15, 2026 |
PRER14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| January 15, 2026 |
SC 13E3 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13E-3 RULE 13E-3 TRANSACTION STATEMENT UNDER SECTION 13(e) OF THE SECURITIES ACT OF 1934 APTOSE BIOSCIENCES INC. (Name of the Issuer) Aptose Biosciences Inc. Hanmi Science Co. Ltd. Hanmi Pharmaceutical Co. Ltd. HS North America Ltd. (Names of Persons Filing Statement) Common Shares, no par value (Title of Class of Securitie |
|
| January 15, 2026 |
Table 1: Transaction Valuation Calculation of Filing Fee Tables Table 1: Transaction Valuation Transaction Valuation Fee Rate Amount of Filing Fee Fees to be Paid 1 $ 3,508,318. |
|
| December 19, 2025 |
EXHIBIT 99.1 Aptose Biosciences Announces Rescheduling of Special Meeting of Shareholders to Approve the Acquisition by Hanmi Pending Final Clearance from SEC SAN DIEGO and TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) - Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF) announced today that it will be rescheduling its upcoming special meeting of shareholders, originally schedule |
|
| December 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2025 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2025 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 8, 2025 |
EXHIBIT 99.1 Aptose’s Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed AML patients with diverse mutations Safety continues to be a notable hallmark of TUS-based therapies 100% resp |
|
| December 5, 2025 |
Table 1: Transaction Valuation Calculation of Filing Fee Tables Table 1: Transaction Valuation Proposed Maximum Aggregate Value of Transaction Fee Rate Amount of Filing Fee Fees to be Paid 1 $ 3,508,318. |
|
| December 5, 2025 |
PREM14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| November 25, 2025 |
EX-2.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [Redacted for confidentiality reasons], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Exhibit 2.1 APTOSE BIOSCIENCES INC. and HS NORTH AMERICA LTD. and HANMI PHARMACEUTICAL CO. LTD. ARRANGEMENT AGREEMENT NOVEMBER 18, 2025 CERTAIN CONFIDENTIAL INFORMATIO |
|
| November 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2025 APTOSE BIOSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2025 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 19, 2025 |
EXHIBIT 99.1 Aptose Biosciences Announces Arrangement Agreement for Acquisition by Hanmi Pharmaceutical Aptose Biosciences minority shareholders to receive C$2.41 in cash per share in a “go private” transaction SAN DIEGO and TORONTO, Nov. 19, 2025 (GLOBE NEWSWIRE) - Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF) and Hanmi Pharmaceutical Co. Ltd. (“Hanmi”) today announce |
|
| November 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q on UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 1-32001 APTOSE BIOSCIEN |
|
| November 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2025 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 13, 2025 |
Aptose Reports Third Quarter 2025 Results EXHIBIT 99.1 Aptose Reports Third Quarter 2025 Results Tuspetinib Continues to Demonstrate Excellent Safety and Complete Responses in the TUSCANY Clinical Trial of Tuspetinib in AML Triple Drug Frontline Therapy at Increased Dose Levels Patients are Now Being Treated at 160 mg Dose of Tuspetinib SAN DIEGO and TORONTO, Nov. 13, 2025 (GLOBE NEWSWIRE) - Aptose Biosciences Inc. (“Aptose” or the “Compa |
|
| November 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2025 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 3, 2025 |
EXHIBIT 99.1 Aptose Tuspetinib Clinical Data from Ongoing TUSCANY Trial in Newly Diagnosed AML Selected for Presentation at the 2025 ASH Annual Meeting Abstract available on ASH website SAN DIEGO and TORONTO, Nov. 03, 2025 (GLOBE NEWSWIRE) - Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug fr |
|
| October 16, 2025 |
EXHIBIT 99.1 Aptose’s Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML Data from Phase 1/2 TUSCANY trial presented at the European School of Haematology (ESH) 7th International Conference Addition of TUS to VEN+AZA achieves CR/CRh responses in all (6/6, 100%) patients treated at the higher dose levels of 80 mg and 120 m |
|
| October 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2025 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission |
|
| September 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2025 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| September 22, 2025 |
EXHIBIT 99.1 Aptose and Hanmi Pharmaceutical Extend Loan Agreement to Continue Development of Tuspetinib in Triplet Therapy for AML SAN DIEGO and TORONTO, Sept. 22, 2025 (GLOBE NEWSWIRE) - Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with ne |
|
| August 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2025 APTOSE BIOSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2025 APTOSE BIOSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 27, 2025 |
EX-16.1 Exhibit 16.1 KPMG LLP 100 New Park Place, Suite 1400 Vaughan, ON L4K 0J3 Tel 905-265 5900 Fax 905-265 6390 www.kpmg.ca To Securities and Exchange Commission Washington, DC August 21, 2025 Dear Sir/Madam Re: Notice of Change of Auditors of Aptose Biosciences Inc. We have read the statements made by Aptose Biosciences Inc. (the “Company”) set forth in Item 4.01 “Changes in Registrant’s Certi |
|
| August 25, 2025 |
EXHIBIT 99.1 Aptose Biosciences Announces Results of Reconvened Annual and Special Shareholders Meeting and Appointment of Ernst & Young LLP as New Auditor Aptose also Receives Additional Advance from Hanmi Pharmaceutical to Continue Development of Tuspetinib in Triplet Therapy for AML SAN DIEGO and TORONTO, Aug. 22, 2025 (GLOBE NEWSWIRE) - Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: |
|
| August 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2025 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2025 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 22, 2025 |
EXHIBIT 99.1 Aptose Biosciences Announces Results of Reconvened Annual and Special Shareholders Meeting and Appointment of Ernst & Young LLP as New Auditor Aptose also Receives Additional Advance from Hanmi Pharmaceutical to Continue Development of Tuspetinib in Triplet Therapy for AML SAN DIEGO and TORONTO, Aug. 22, 2025 (GLOBE NEWSWIRE) - Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: |
|
| August 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2025 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 18, 2025 |
EXHIBIT 99.1 Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial Addition of Tuspetinib (TUS) to Venetoclax (VEN) and Azacitidine (AZA) is being developed as safe and mutation agnostic frontline therapy for AML Addition of TUS to VEN+AZA improves response rates; 100% CR/CRh at 80 mg and |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q on UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 1-32001 APTOSE BIOSCIENCES I |
|
| August 13, 2025 |
Aptose Reports Second Quarter 2025 Results EXHIBIT 99.1 Aptose Reports Second Quarter 2025 Results Tuspetinib Continues to Demonstrate Excellent Safety and Complete Responses in the TUSCANY Clinical Trial of Tuspetinib in AML Triple Drug Frontline Therapy at 120 mg Dose Cohort Safety Review Committee (CSRC) Recommends Tuspetinib Dose Escalation to 160 mg Dose Hanmi Continues to Support Development of Tuspetinib SAN DIEGO and TORONTO, Aug. |
|
| August 6, 2025 |
EXHIBIT 99.1 Aptose Enrollment is Open for 160 mg Dosing Cohort of Tuspetinib in Phase 1/2 TUSCANY Trial of Frontline Triple Drug Therapy Safety Review Committee endorses escalation to 160 mg TUS dosing Cohorts with 120 mg, 80 mg, 40 mg TUS dosing completed with no dose-limiting toxicities Excellent safety and complete remissions (CRs) in some of the most difficult-to-treat AML populations No dose |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for use of the Commission Only (as permitted by Ru |
|
| July 15, 2025 |
EXHIBIT 99.1 Aptose Receives Second Advance under the Loan Agreement with Hanmi Pharmaceutical to Continue Development of Tuspetinib in Triplet Therapy for AML SAN DIEGO and TORONTO, July 15, 2025 (GLOBE NEWSWIRE) - Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therap |
|
| July 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2025 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| July 2, 2025 |
Aptose Announces Deferral of Interest Payment EX-99.1 Exhibit 99.1 For Immediate Release Aptose Announces Deferral of Interest Payment SAN DIEGO and TORONTO, June 30, 2025 — Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), announced that it |
|
| July 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2025 APTOSE BIOSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| July 2, 2025 |
Interest Deferral Agreement, dated June 24, 2025, between Hanmi and the Company Exhibit 10.1 Confidental EXECUTION VERSION INTEREST PAYMENT AGREEMENT This Interest Payment Agreement (this “Agreement”), dated June 24, 2025 (the “Effective Date”), is entered into by and between Aptose Biosciences Inc., a corporation incorporated pursuant to the Canada Business Corporations Act (the “Company”), and Hanmi Pharmaceutical Co., Ltd. (the “Lender”), a corporation incorporated under t |
|
| July 1, 2025 |
EXHIBIT 99.1 Aptose Upgraded to Trade on OTCQB Market Aptose will trade under the ticker symbol APTOF and begin trading on OTCQB today, July 1st SAN DIEGO and TORONTO, July 01, 2025 (GLOBE NEWSWIRE) - Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat pati |
|
| July 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2025 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 26, 2025 |
Exhibit 10.1 Execution Version 2025 FACILITY AGREEMENT between Hanmi Pharmaceutical Co., Ltd., as Lender and Aptose Biosciences Inc., as Borrower and Aptose Biosciences U.S. Inc. and NuChem Pharmaceuticals Inc., each as a Guarantor This 2025 facility agreement is dated June 18, 2025. PARTIES Hanmi Pharmaceutical Co., Ltd. incorporated and registered in the Republic of Korea (the “Lender”) and Apto |
|
| June 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2025 APTOSE BIOSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| June 20, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2025 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| June 20, 2025 |
EXHIBIT 99.1 Aptose and Hanmi Enter New Loan Agreement to Advance Development of Tuspetinib in Triplet Therapy for AML SAN DIEGO and TORONTO, June 20, 2025 (GLOBE NEWSWIRE) - Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed |
|
| June 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2025 APTOSE BIOSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| June 17, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025 APTOSE BIOSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| June 17, 2025 |
Aptose Provides Corporate Updates EXHIBIT 99.1 Aptose Provides Corporate Updates Announces short-term cash advance SAN DIEGO and TORONTO, June 17, 2025 (GLOBE NEWSWIRE) - Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company, announced today that the Company has secured a short-term cash advance from Dr. William G. Rice, the Company’s Chairman of the Board, Presiden |
|
| June 12, 2025 |
EXHIBIT 99.1 Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress Addition of TUS to standard of care VEN+AZA creates a well-tolerated and mutation agnostic frontline triple drug therapy for newly diagnosed AML AML patients with diverse mutations, including TP53-mutated/CK and FLT |
|
| June 12, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2025 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 28, 2025 |
Aptose Announces Results from Annual and Special Meeting of Shareholders EXHIBIT 99.1 Aptose Announces Results from Annual and Special Meeting of Shareholders SAN DIEGO and TORONTO, May 27, 2025 (GLOBE NEWSWIRE) - Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), toda |
|
| May 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2025 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 20, 2025 |
EXHIBIT 99.1 Aptose Announces Dosing of First Patient with 120 mg of Tuspetinib in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy after Dose Escalation Decision by Safety Review Committee TUS+VEN+AZA triplet achieves complete remissions (CRs) and minimal residual disease (MRD)-negativity with favorable safety in newly diagnosed AML patients Completed 40 mg and 80 mg TUS dose cohorts; no |
|
| May 20, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2025 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 14, 2025 |
EXHIBIT 99.1 Aptose Selected for Prestigious Oral Presentation of Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress Aptose is developing TUS+VEN+AZA as a one-of-a-kind safe and mutation agnostic frontline triple drug therapy for newly diagnosed AML Oral presentation at EHA will include updated data at the 40 mg and 80 mg dose l |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q on UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 1-32001 APTOSE BIOSCIENCES |
|
| May 8, 2025 |
EXHIBIT 99.1 Aptose Reports First Quarter 2025 Results Highlights Progress in TUSCANY Clinical Trial of Tuspetinib in AML Triple Frontline Therapy SAN DIEGO and TORONTO, May 08, 2025 (GLOBE NEWSWIRE) - Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS)-based triple drug frontline therapy to treat |
|
| May 8, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 5, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 5, 2025 |
EXHIBIT 99.1 Aptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial Aptose is developing TUS+VEN+AZA as a one-of-a-kind safe and mutation agnostic frontline triple drug therapy for newly diagnosed AML patients First two dose cohorts of TUS+VEN+AZA triplet demonstrate safety, complete remissions, and MR |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| April 28, 2025 |
April 28, 2025 William Rice Chief Executive Officer Aptose Biosciences Inc. 12770 High Bluff Drive, Unit 120 San Diego, CA 92130 Re: Aptose Biosciences Inc. Preliminary Proxy Statement on Schedule 14A Filed April 23, 2025 File No. 001-32001 Dear William Rice: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy |
|
| April 23, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2025 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| April 23, 2025 |
Aptose Announces Auditor Not Standing for Re-Appointment EXHIBIT 99.1 Aptose Announces Auditor Not Standing for Re-Appointment SAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) - Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX:APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), announces that effective on Apr |
|
| April 23, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| April 21, 2025 |
Letter from KPMG LLP to the Securities and Exchange Commission EX-16.1 Exhibit 16.1 KPMG LLP 100 New Park Place, Suite 1400 Vaughan, ON L4K 0J3 Tel 905-265 5900 Fax 905-265 6390 www.kpmg.ca To: United States Securities and Exchange Commission April 21, 2025 Dear Sir/Madam Re: Notice of Change of Auditors of Aptose Biosciences Inc. We have read the Notice of Aptose Biosciences Inc. in this Form 8-K dated April 21, 2025 and are in agreement with the statements |
|
| April 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2025 APTOSE BIOSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| April 17, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| April 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 APTOSE BIOSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2025 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| April 1, 2025 |
Aptose Common Shares to Delist from Nasdaq as of April 2, 2025 EXHIBIT 99.1 Aptose Common Shares to Delist from Nasdaq as of April 2, 2025 SAN DIEGO and TORONTO, April 01, 2025 (GLOBE NEWSWIRE) - Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX:APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today annou |
|
| March 28, 2025 |
Aptose Bioscience Inc. Clawback Policy e Exhibit 97.1 APTOSE BIOSCIENCES INC. INCENTIVE COMPENSATION RECOVERY POLICY 1. Introduction. The Board of Directors of Aptose Biosciences Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company's compensation philosophy. The Board has therefore |
|
| March 28, 2025 |
Exhibit 19.1 AMENDED AND REINSTATED DISCLOSURE AND INSIDER TRADING POLICY APTOSE BIOSCIENCES INC. (the “Company”) As revised and adopted by the Board of Directors (the “Board”) on May 5, 2020 I. OBJECTIVES AND SCOPE 1.1. Objectives The Company is committed to best practices in making timely and accurate disclosure of all material information and providing fair and equal access to material informat |
|
| March 28, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2025 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| March 28, 2025 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-32001 Aptose Bioscien |
|
| March 28, 2025 |
Exhibit 21.1 Subsidiaries of the Registrant Name State/Jurisdiction of Incorporation Aptose Biosciences U.S. Inc. Delaware NuChem Pharmaceuticals Inc. Ontario, Canada |
|
| March 28, 2025 |
EXHIBIT 99.1 Aptose Reports Year End 2024 Results and Corporate Highlights Tuspetinib Triple Drug Frontline Therapy Advancing in TUSCANY Clinical Trial Results to Date Highlight TUS Potential as an Ideal Third Drug to Include in AML Triplet Therapy Aptose Signs Debt Conversion Agreement with Hanmi SAN DIEGO and TORONTO, March 28, 2025 (GLOBE NEWSWIRE) - Aptose Biosciences Inc. (“Aptose” or the “Co |
|
| March 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2025 APTOSE BIOSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| March 24, 2025 |
Debt Conversion and Interest Payment Agreement, dated March 18, 2025 Exhibit 10.1 Certain portions of this Exhibit have been redacted pursuant to Item 601(b)(10) of Regulation S-K and, where applicable, have been marked with “[***]” to indicate where redactions have been made. The marked information has been redacted because it is both (i) not material and (ii) is the type of information the Corporation treats as private and confidential. DEBT CONVERSION AND INTERE |
|
| March 24, 2025 |
Second Amended and Restated Investor’s Rights Agreement, dated March 18, 2025 EX-10.2 Exhibit 10.2 Certain portions of this Exhibit have been redacted pursuant to Item 601(b)(10) of Regulation S-K and, where applicable, have been marked with “[***]” to indicate where redactions have been made. The marked information has been redacted because it is both (i) not material and (ii) is the type of information the Corporation treats as private and confidential. SECOND AMENDED AND |
|
| March 17, 2025 |
Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance EXHIBIT 99.1 Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance SAN DIEGO and TORONTO, March 17, 2025 (GLOBE NEWSWIRE) - Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today anno |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2025 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| March 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2025 APTOSE BIOSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| March 12, 2025 |
Exhibit 99.1 Aptose Precision oncology company developing oral targeted agents to treat hematologic malignancies C o r p o r a t e P r e s e n t a t i o n M a r c h 2025 Tuspetinib in Frontline Triple Drug Therapy to Treat Newly Diagnosed AML 1 NASDAQ: APTO TSX: APS AML (Acute Myeloid Leukemia) • Highly aggressive and deadly cancer of the bone marrow and blood Current Frontline (1L) Standard of Ca |
|
| February 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2025 APTOSE BIOSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 21, 2025 |
Exhibit 3.1 Innovation, Science and Economic Development Canada Corporations Canada Innovation, Sciences et Développement économique Canada Corporations Canada Certificate of Amendment Certificat de modification Canada Business Corporations Act Loi canadienne sur les sociétés par actions Aptose Biosciences Inc. Corporate name / Dénomination sociale 665030-9 Corporation number / Numéro de société I |
|
| February 20, 2025 |
EXHIBIT 99.1 Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort TUS+VEN+AZA triplet achieves complete responses (CRs) in difficult-to-treat TP53-mutated/CK AML and FLT3-wildtype AML patients, including a measurable residua |
|
| February 20, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2025 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 18, 2025 |
Aptose Announces Reverse Share Split EXHIBIT 99.1 Aptose Announces Reverse Share Split SAN DIEGO and TORONTO, Feb. 18, 2025 (GLOBE NEWSWIRE) - Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed AML, today announced that its board of directors (the “Board”) ha |
|
| February 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2025 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 13, 2025 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of February 7, 2025, is by and between Keystone Capital Partners, LLC, a Delaware limited liability company (the “Investor”), and Aptose Biosciences Inc., a corporation organized under the laws of Canada (the “Company”). RECITALS A. The Company and the Investor have entered into that certain |
|
| February 13, 2025 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2025 APTOSE BIOSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2025 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 13, 2025 |
Exhibit 10.28 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of February 7, 2025, is by and between Keystone Capital Partners, LLC, a Delaware limited liability company (the “Investor”), and Aptose Biosciences Inc., a corporation organized under the laws of Canada (the “Company”). RECITALS A. The Company and the Investor have entered into that certain |
|
| February 13, 2025 |
Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility Exhibit 99.1 Not For Immediate Release – confidential for review Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility SAN DIEGO and TORONTO, February 13, 2025 - Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based triple drug frontline therapy to |
|
| February 13, 2025 |
Exhibit 10.27 COMMON SHARE PURCHASE AGREEMENT Dated as of February 7, 2025 by and among APTOSE BIOSCIENCES INC., And KEYSTONE CAPITAL PARTNERS, LLC TABLE OF CONTENTS Page ARTICLE I PURCHASE AND SALE OF COMMON SHARES 1 Section 1.1. Purchase and Sale of Stock 1 Section 1.2. Closing Date; Settlement Dates 1 Section 1.3. Initial Public Announcements and Required Filings 2 ARTICLE II PURCHASE TERMS 3 S |
|
| February 13, 2025 |
As filed with the Securities and Exchange Commission on February 13, 2025 S-1 Table of Contents As filed with the Securities and Exchange Commission on February 13, 2025 Registration No. |
|
| February 13, 2025 |
Exhibit 99.2 The identity and the Item 3 classification of the relevant subsidiary is: Bleichroeder LP, which is an Investment Adviser in accordance with Rule 13d-1(b)(1)(ii)(E). |
|
| February 13, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-1 (Form Type) Aptose Biosciences Inc. |
|
| February 13, 2025 |
Exhibit 10.1 COMMON SHARE PURCHASE AGREEMENT Dated as of February 7, 2025 by and among APTOSE BIOSCIENCES INC., And KEYSTONE CAPITAL PARTNERS, LLC TABLE OF CONTENTS Page ARTICLE I PURCHASE AND SALE OF COMMON SHARES 1 Section 1.1. Purchase and Sale of Stock 1 Section 1.2. Closing Date; Settlement Dates 1 Section 1.3. Initial Public Announcements and Required Filings 2 ARTICLE II PURCHASE TERMS 3 |
|
| February 13, 2025 |
Exhibit 99.1 AGREEMENT OF THE REPORTING PERSONS The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that e |
|
| February 13, 2025 |
Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility EXHIBIT 99.1 Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility SAN DIEGO and TORONTO, Feb. 13, 2025 (GLOBE NEWSWIRE) - Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed AM |
|
| February 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2025 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 12, 2025 |
EXHIBIT 99.1 Aptose’s Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial TUS+VEN+AZA triplet achieves Cycle 1 complete remission (CR) in TP53-mutated/CK AML TUS+VEN+AZA triplet achieves Cycle 1 complete remissions in FLT3-wildtype AML patients TUS+VEN+AZA triplet shows favorable safety with no alteration of VEN an |
|
| February 3, 2025 |
Exhibit 10.1 APTOSE BIOSCIENCES INC. COMMON SHARES SALES AGREEMENT February 3, 2025 A.G.P./Alliance Global Partners 590 Madison Avenue New York, NY 10022 Ladies and Gentlemen: Aptose Biosciences Inc., a company incorporated under the laws of Canada (the “Company”), confirms its agreement (this “Agreement”) with A.G.P./Alliance Global Partners (the “Sales Agent”), as follows: 1. Issuance and Sale o |
|
| February 3, 2025 |
$1,000,000 Aptose Biosciences Inc. Common Shares Table of Contents Filed pursuant to 424(b)(5) Registration No. 333-267801 PROSPECTUS SUPPLEMENT (to Prospectus dated October 21, 2022) $1,000,000 Aptose Biosciences Inc. Common Shares On February 3, 2025, we entered into a certain sales agreement (the “Sales Agreement”) with A.G.P./Alliance Global Partners (the “A.G.P”) relating to our common shares offered by this prospectus supplement. In accord |
|
| February 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2025 APTOSE BIOSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2025 APTOSE BIOSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 January 14, 2025 (Date of Report - date of earliest event reported) Aptose Biosciences Inc. (Exact Name of Registrant as Specified in Its Charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation or Organizat |
|
| January 13, 2025 |
Exhibit 99.1 Aptose Precision oncology company developing oral targeted agents to treat hematologic malignancies Corporate Presentation January 2025 Tuspetinib in Frontline Triple Drug Therapy to Treat Newly Diagnosed AML 1 NASDAQ: APTO TSX: APS AML (Acute Myeloid Leukemia) • Highly aggressive and deadly cancer of the bone marrow and blood Current Standard of Care Therapy • VEN+AZA (Venetoclax + A |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 APTOSE BIOSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 10, 2025 |
EXHIBIT 99.1 Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial TUS+VEN+AZA triplet has potential as frontline therapy to treat large, mutationally diverse populations of AML SAN DIEGO and TORONTO, Jan. 09, 2025 (GLOBE NEWSWIRE) - Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology compa |
|
| January 10, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2025 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| December 30, 2024 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| December 30, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| December 19, 2024 |
Aptose Announces Positive Decision by Nasdaq Hearings Panel EXHIBIT 99.1 Aptose Announces Positive Decision by Nasdaq Hearings Panel SAN DIEGO and TORONTO, Dec. 19, 2024 (GLOBE NEWSWIRE) - Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic malignancies, today announced that the Nasdaq Hearings Panel (“Panel”) has gran |
|
| December 19, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2024 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 13, 2024 |
PRE 14A 1 d866874dpre14a.htm PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Prox |
|
| December 12, 2024 |
EXHIBIT 99.1 Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax Peer-reviewed publication details unique TUS mechanism of action TUS+VEN combination synthetic lethality overcomes resistance to VEN Tuspetinib prolongs survival in multiple AML models resistant to oth |
|
| December 12, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2024 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 9, 2024 |
EXHIBIT 99.1 Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML TUS+VEN+AZA Triplet Frontline Therapy in Newly Diagnosed AML Patients Now Enrolling at U.S. Sites TUS and TUS+VEN Broadly Active Across AML Populations, with Favorable Safety TUS-based therapies are active in FLT3 wildtype, representing ~70 |
|
| December 9, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2024 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 3, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2024 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 3, 2024 |
EXHIBIT 99.1 Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials Tuspetinib selected for a prestigious national clinical research program for ability to target broad spectrum of AML and MDS populations Trials to test tuspetinib in targeted drug combinations for frontline therapy of molecularly defined sub-groups of newly diagnose |
|
| November 25, 2024 |
Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering EX-99.1 Exhibit 99.1 For Immediate Release Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering SAN DIEGO and TORONTO, November 25, 2024 — Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced the closing of |
|
| November 25, 2024 |
424B4 Table of Contents Filed Pursuant to 424(b)(4) Registration No. (333-281201) PROSPECTUS Up to 40,000,000 Common Shares Up to 20,000,000 Common Warrants to Purchase 20,000,000 Common Shares Up to 20,000,000 Common Shares Underlying Common Warrants Up to 1,600,000 Common Shares underlying the Placement Agent Warrants This prospectus relates to the offering of up to 40,000,000 common shares, no |
|
| November 25, 2024 |
Form of Placement Agent Warrant EX-4.2 Exhibit 4.2 PLACEMENT AGENT COMMON SHARE PURCHASE WARRANT APTOSE BIOSCIENCES INC. Warrant Shares: Issue Date: November [•], 2024 THIS PLACEMENT AGENT COMMON SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or |
|
| November 25, 2024 |
EX-10.1 Exhibit 10.1 PLACEMENT AGENCY AGREEMENT November 21, 2024 Aptose Biosciences Inc. 251 Consumers Road, Suite 1105 Toronto, Ontario, Canada M2J 4R3 Attention: William G. Rice, Ph.D. Dear Dr. Rice: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners, as placement agent (the “Placement Agent”), and Aptose Biosciencs Inc., a company incorporated under |
|
| November 25, 2024 |
EX-4.1 Exhibit 4.1 COMMON SHARE PURCHASE WARRANT APTOSE BIOSCIENCES INC. Warrant Shares: Issue Date: November [•], 2024 THIS COMMON SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof ( |
|
| November 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2024 APTOSE BIOSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or other jurisdiction of incorporation) (Commission |
|
| November 22, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2024 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 22, 2024 |
Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering EXHIBIT 99.1 Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering SAN DIEGO and TORONTO, Nov. 22, 2024 (GLOBE NEWSWIRE) - Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced the pricing of its "reasonable b |
|
| November 20, 2024 |
EXHIBIT 99.1 Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy TUSCANY study is open to enroll patients to receive TUS+VEN+AZA triplet at select US sites Favorable safety and broad clinical activity make tuspetinib an ideal agent to combine with venetoclax and azacitidine to potentially address larger AML populations Study executi |
|
| November 20, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2024 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 19, 2024 |
CORRESP Aptose Biosciences, Inc. 66 Wellington Street West, Suite 5300 TD Bank Tower Box 48 Toronto, Ontario, Canada November 19, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attention: Jimmy McNamara Re: Aptose Biosciences Inc. – Registration Statement on Form S-1 (File No. 333-281201) Ladies and Gentlem |
|
| November 19, 2024 |
November 19, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jimmy McNamara Re: Aptose Biosciences Inc. Registration Statement on Form S-1 File No. 333-281201 Ladies and Gentlemen: In accordance with Rule 461 of the General Rules and Regulations promulgated under the Securities Act of 1933, as amended (the |
|
| November 14, 2024 |
APTO / Aptose Biosciences Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G 1 armistice-apto093024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Aptose Biosciences Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 03835T309 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate b |
|
| November 12, 2024 |
Facility Agreement among the Company and Hanmi Pharmaceutical Co., Ltd dated August 27, 2024 Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. FACILITY AGREEMENT between Hanmi Pharmaceutical Co., Ltd. and Aptose Biosciences Inc. This agreement (“Agreement”) is dated August 27, 2024. PARTIES (1) Hanmi Pharmaceutical Co., Ltd. incorporated |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q on UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 1-32001 APTOSE BIOSCIEN |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2024 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 8, 2024 |
EXHIBIT 99.1 Aptose Reports Results for the Third Quarter 2024 Aptose and Hanmi Pharmaceutical Co-developing Triplet Therapy of Tuspetinib with Azacitidine and Venetoclax for Newly Diagnosed AML SAN DIEGO and TORONTO, Nov. 08, 2024 (GLOBE NEWSWIRE) - Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly different |
|
| October 31, 2024 |
Exhibit 4.3 PRE-FUNDED COMMON SHARES PURCHASE WARRANT APTOSE BIOSCIENCES INC. Warrant Shares: Issue Date: October [•], 2024 THIS PRE-FUNDED COMMON SHARES PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date h |
|
| October 31, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Aptose Biosciences Inc. |
|
| October 31, 2024 |
CORRESP DANIEL M. MILLER Partner (604) 630-5199 FAX (604) 687-8504 [email protected] October 30, 2024 Division of Corporation Finance Office of Life Sciences U.S. Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Attention: Jimmy McNamara and Joe McCann Re: Aptose Biosciences Inc. Registration Statement on Form S-1 Filed August 2, 2024 File No. 333-281201 Dear Sirs a |
|
| October 31, 2024 |
Form of Placement Agent Warrant Exhibit 4.4 PLACEMENT AGENT COMMON SHARE PURCHASE WARRANT APTOSE BIOSCIENCES INC. Warrant Shares: Issue Date: October [•], 2024 THIS PLACEMENT AGENT COMMON SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on |
|
| October 31, 2024 |
Exhibit 4.2 COMMON SHARE PURCHASE WARRANT APTOSE BIOSCIENCES INC. Warrant Shares: Issue Date: October [•], 2024 THIS COMMON SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Init |
|
| October 31, 2024 |
S-1/A Table of Contents Registration No. 333-281201 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 to FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 APTOSE BIOSCIENCES INC. (Exact name of Registrant as specified in its charter) Canada 2836 98-1136802 (State or other jurisdiction of incorporation or organization) (Primary Standard Industria |
|
| October 31, 2024 |
Form of Securities Purchase Agreement Exhibit 10.24 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of October [•], 2024, between Aptose Biosciences Inc., a Canadian corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condit |
|
| October 31, 2024 |
Form of Placement Agency Agreement Exhibit 10.23 PLACEMENT AGENCY AGREEMENT October [•], 2024 Aptose Biosciences Inc. 251 Consumers Road, Suite 1105 Toronto, Ontario, Canada M2J 4R3 Attention: William G. Rice, Ph.D. Dear Dr. Rice: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners, as placement agent (the “Placement Agent”), and Aptose Biosciencs Inc., a company incorporated under the la |
|
| October 4, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2024 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| September 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2024 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission |
|
| September 5, 2024 |
Aptose Announces Results from Special Meeting of Shareholders EXHIBIT 99.1 Aptose Announces Results from Special Meeting of Shareholders SAN DIEGO and TORONTO, Sept. 05, 2024 (GLOBE NEWSWIRE) - Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing tuspetinib, a highly differentiated oral kinase inhibitor for the treatment of patients with acute myeloid leukemia (AML), announced th |
|
| September 5, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2024 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2024 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 30, 2024 |
EXHIBIT 99.1 Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib Proceeds to be used for development of lead compound tuspetinib in combination therapy as frontline treatment for newly diagnosed AML patients SAN DIEGO and TORONTO, Aug. 30, 2024 (GLOBE NEWSWIRE) - Aptose Biosciences Inc. (“Aptose” o |
|
| August 15, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2024 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 15, 2024 |
Aptose Announces Adjournment of its Special Meeting of Shareholders EXHIBIT 99.1 Aptose Announces Adjournment of its Special Meeting of Shareholders SAN DIEGO and TORONTO, Aug. 15, 2024 (GLOBE NEWSWIRE) - Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced that its special meeting of sharehol |
|
| August 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q on UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 1-32001 APTOSE BIOSCIENCES I |
|
| August 8, 2024 |
Aptose Reports Results for the Second Quarter 2024 EXHIBIT 99.1 Aptose Reports Results for the Second Quarter 2024 TUS+VEN+HMA Triplet Protocol in Frontline Therapy for Newly Diagnosed AML was Reviewed by the FDA and Allowed to Proceed Abstract Supporting Exploration of the TUS+VEN+AZA Triplet in Frontline Therapy for Newly Diagnosed AML has been Submitted to the 2025 Annual Meeting of the American Society of Hematology (ASH) SAN DIEGO and TORONTO |
|
| August 2, 2024 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) APTOSE BIOSCIENCES INC. |
|
| August 2, 2024 |
August 2, 2024 William G. Rice Chief Executive Officer Aptose Biosciences Inc. Unit 120 12770 High Bluff Drive San Diego, California 92130 Re: Aptose Biosciences Inc. Registration Statement on Form S-1 Filed August 2, 2024 File No. 333-281201 Dear William G. Rice: We have conducted a limited review of your registration statement and have the following comment. Please respond to this letter by amen |
|
| August 2, 2024 |
As filed with the Securities and Exchange Commission on August 1, 2024 S-1 Table of Contents As filed with the Securities and Exchange Commission on August 1, 2024 Registration No. |
|
| July 26, 2024 |
Exhibit 99.1 Aptose Precision oncology company developing oral targeted agents to treat hematologic malignancies C o r p o r a t e P r e s e n t a t i o n J u l y 26 , 2024 Tuspetinib to Treat Newly Diagnosed AML Aptose Disclosure 2 This presentation does not, and is not intended to, constitute or form part of, and should not be construed as, an offer or invitation for the sale or purchase of, or |
|
| July 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2024 APTOSE BIOSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| July 19, 2024 |
Aptose Announces Receipt of Deficiency Notice from Nasdaq EXHIBIT 99.1 Aptose Announces Receipt of Deficiency Notice from Nasdaq SAN DIEGO and TORONTO, July 19, 2024 (GLOBE NEWSWIRE) - Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced that it has received a deficiency letter (the |
|
| July 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2024 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| July 17, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| July 5, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| June 20, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2024 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| June 20, 2024 |
Aptose Announces Results from Annual and Special Meeting of Shareholders EXHIBIT 99.1 Aptose Announces Results from Annual and Special Meeting of Shareholders SAN DIEGO and TORONTO, June 18, 2024 (GLOBE NEWSWIRE) - Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced the voting results from the C |
|
| June 20, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2024 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| June 14, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2024 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| June 14, 2024 |
EXHIBIT 99.1 Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress TUS Monotherapy and TUS+Venetoclax (VEN) Doublet Therapy Show Broad Clinical Activity and Strong Safety Data in relapsed or refractory (R/R) Acute Myeloid Leukemia (AML) and Differentiate TUS from other Investigational Drugs in AML TUS Monotherapy and TUS+VE |
|
| June 3, 2024 |
Form of Placement Agent Common Share Purchase Warrant Exhibit 10.3 PLACEMENT AGENT COMMON SHARE PURCHASE WARRANT APTOSE BIOSCIENCES INC. Warrant Shares: Issue Date: June 3, 2024 THIS PLACEMENT AGENT COMMON SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Sh |
|
| June 3, 2024 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2024 APTOSE BIOSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 3, 2024 |
EXHIBIT 99.1 Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules SAN DIEGO and TORONTO, June 03, 2024 (GLOBE NEWSWIRE) - Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today annou |
|
| June 3, 2024 |
Form of Pre-Funded Common Share Purchase Warrant Exhibit 10.4 PRE-FUNDED COMMON SHARE PURCHASE WARRANT APTOSE BIOSCIENCES INC. Warrant Shares: Issue Date:, 2024 Initial Exercise Date: , 2024 THIS PRE-FUNDED COMMON SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or |
|
| June 3, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2024 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 3, 2024 |
Form of Common Share Purchase Warrant Exhibit 10.2 [SERIES A/SERIES B] COMMON SHARE PURCHASE WARRANT APTOSE BIOSCIENCES INC. Warrant Shares: Issue Date:, 2024 THIS [SERIES A/SERIES B] COMMON SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the S |
|
| June 3, 2024 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-267801 Prospectus Supplement (to Prospectus dated October 21, 2022) 1,800,000 Common Shares 2,055,000 Pre-Funded Warrants to Purchase up to 2,055,000 Common Shares Common Shares Underlying the Pre-Funded Warrants We are offering 1,800,000 common shares, no par value (“Common Shares”), and 2,055,000 pre-funded warrants (the “Pr |
|
| June 3, 2024 |
Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 30, 2024, between Aptose Biosciences Inc., a corporation organized under the laws of Canada (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to |
|
| May 31, 2024 |
Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules EXHIBIT 99.1 Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules SAN DIEGO and TORONTO, May 31, 2024 (GLOBE NEWSWIRE) - Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced that it |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2024 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 15, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| May 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q on UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 1-32001 APTOSE BIOSCIENCES |
|
| May 14, 2024 |
Aptose Reports Results for the First Quarter 2024 EXHIBIT 99.1 Aptose Reports Results for the First Quarter 2024 TUS+VEN+HMA Triplet Protocol in 1L Therapy for Newly Diagnosed AML was Submitted to the FDA During Q1 and is Now Being Activated at Clinical Sites TUS+VEN+HMA Triplet 1L Therapy for Newly Diagnosed AML is Supported by Extensive TUS and TUS+VEN Data from Completed Trials with R/R AML Conference Call and Webcast at 5:00 pm ET Today SAN D |
|
| May 6, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2024 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 6, 2024 |
EXHIBIT 99.1 Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024 SAN DIEGO and TORONTO, May 06, 2024 (GLOBE NEWSWIRE) - Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results fo |
|
| May 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 April 29, 2024 (Date of Report - date of earliest event reported) Aptose Biosciences Inc. (Exact Name of Registrant as Specified in Its Charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation or Organizatio |
|
| May 1, 2024 |
Exhibit 10.3 APTOSE BIOSCIENCES INC. AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (the “Agreement”), made between Aptose Biosciences Inc. (the “Company”) and Fletcher Payne (“Executive”), and together with the Company, (the “Parties”), is effective as of April 29, 2024 (the “Effective Date”). WHEREAS the Company and the Executive are |
|
| May 1, 2024 |
Exhibit 10.1 APTOSE BIOSCIENCES INC. SECOND AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT SECOND AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT THIS SECOND AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT is made as of April 29, 2024 BETWEEN: APTOSE BIOSCIENCES INC. (the “Corporation”) - and - DR. WILLIAM G. RICE (the “Executive”) RECITALS: A. The Corporation is involved in the bioph |
|
| May 1, 2024 |
Exhibit 10.2 APTOSE BIOSCIENCES INC. AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (the “Agreement”), made between Aptose Biosciences Inc. (the “Company”) and Rafael Bejar, M.D. Ph.D (“Executive”), and together with the Company, (the “Parties”), is effective as of April 29, 2024 (the “Effective Date”). WHEREAS the Company and the Execu |
|
| April 30, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-32001 Aptose Biosci |
|
| April 26, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| April 26, 2024 |
SC 13D/A 1 ea0204769-13da2hanmiaptose.htm AMENDMENT NO. 2 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) Aptose Biosciences Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 03835T200 (CUSIP Number) Tony Koh Hanmi Pharmaceutical Co., Ltd. 14 Wiryeseong-Da |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2024 APTOSE BIOSCIENCES INC. (Exact name of registrant as specified in its charter) Canada (State or Other Jurisdiction of Incorporation) 001-32001 (Commission File Number) |
|
| April 26, 2024 |
Amended and Restated Warrant to Purchase Common Shares, dated January 31, 2024 EX-99.2 2 ea020476901ex99-2aptose.htm AMENDED AND RESTATED WARRANT TO PURCHASE COMMON SHARES, DATED JANUARY 31, 2024 Exhibit 99.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, A |
|
| April 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 April 2, 2024 (Date of Report - date of earliest event reported) Aptose Biosciences Inc. (Exact Name of Registrant as Specified in Its Charter) Canada (State or Other Jurisdiction of Incorporation or Organization) 001-32001 (Commissi |
|
| March 26, 2024 |
Aptose Bioscience Inc. Clawback Policy e Exhibit 97.1 APTOSE BIOSCIENCES INC. INCENTIVE COMPENSATION RECOVERY POLICY 1. Introduction. The Board of Directors of Aptose Biosciences Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company's compensation philosophy. The Board has therefore |
|
| March 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-32001 Aptose Bioscien |
|
| March 26, 2024 |
Exhibit 21.1 Subsidiaries of the Registrant Name State/Jurisdiction of Incorporation Aptose Biosciences U.S. Inc. Delaware NuChem Pharmaceuticals Inc. Ontario, Canada |
|
| March 26, 2024 |
Aptose Reports Results for the Fourth Quarter and Full Year 2023 EXHIBIT 99.1 Aptose Reports Results for the Fourth Quarter and Full Year 2023 Tuspetinib to Advance to TUS+VEN+HMA Triplet Therapy Pilot Study in 1L AML Tuspetinib Continues Broad Activity Across Mutations with Excellent Safety Profile Luxeptinib G3 Formulation Achieves Desired Levels and Positions for Future Trials Conference Call and Webcast at 5:00 pm ET Today SAN DIEGO and TORONTO, March 26, 2 |
|
| March 26, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2024 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| March 18, 2024 |
EXHIBIT 99.1 Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024 SAN DIEGO and TORONTO, March 18, 2024 (GLOBE NEWSWIRE) - Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial |
|
| March 18, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2024 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| March 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 February 29, 2024 (Date of Report - date of earliest event reported) Aptose Biosciences Inc. (Exact Name of Registrant as Specified in Its Charter) Canada (State or Other Jurisdiction of Incorporation or Organization) 001-32001 (Comm |
|
| February 14, 2024 |
APTO / Aptose Biosciences Inc. / Nantahala Capital Management, LLC - SC 13G/A Passive Investment SC 13G/A 1 tm243309d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Aptose Biosciences Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 03835T200 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appr |
|
| February 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1) Aptose Biosciences Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 03835T200 (CUSIP Number) Tony Koh Hanmi Pharmaceutical Co., Ltd. 14 Wiryeseong-Daero, Songpa-Gu Seoul, Republic of Korea, 05545 +82 (2) 410 0436 with a c |
|
| February 5, 2024 |
EX-99.1 2 ea192731ex99-1aptose.htm SUBSCRIPTION AGREEMENT, DATED AS OF JANUARY 25, 2024, BY AND BETWEEN THE REPORTING PERSON AND THE ISSUER Exhibit 99.1 EXECUTION PAGE - SUBSCRIPTION FOR COMMON SHARES AND WARRANTS TO: Aptose Biosciences Inc. (the “Corporation”) The undersigned (the “Subscriber’’) hereby irrevocably subscribes for and agrees to purchase from Aptose Biosciences Inc. (the “Corporatio |
|
| January 31, 2024 |
EXHIBIT 99.1 Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option SAN DIEGO and TORONTO, Jan. 31, 2024 (GLOBE NEWSWIRE) - Aptose Biosciences Inc. (“Aptose” or the “Company”) (Nasdaq: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated |
|
| January 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2024 Aptose Biosciences Inc. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2024 APTOSE BIOSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission |
